Other (Income)/Deductions - Net (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2018	Apr. 02, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalty-related income		$ (7)	$ (7)
Foreign currency loss	[1]	8	2
Other, net	[2]	(6)	(5)
Other (income)/deductions—net		$ (5)	$ (10)

[1] Primarily driven by costs related to hedging and exposures to certain emerging market currencies.

[2] For the three months ended April 2, 2017, primarily includes a settlement refund and reimbursement of legal fees related to costs incurred by Pharmaq prior to the acquisition in 2015, as well as interest income and other miscellaneous income.